OBJECTIVE: We conducted a retrospective cohort study to compare the use of triple therapy versus monotherapy for children and adolescents with perforated appendicitis and to determine whether there has been a transition to monotherapy within the freestanding children's hospitals that contribute to the Pediatric Health Information System database. METHODS: We used the Pediatric Health Information System database, which includes billing and discharge data for 32 children's hospitals in the United States, to examine the trend in antibiotic usage and whether the postappendectomy antibiotic regimen was associated with differences in complication-related readmissions, length of stay, or charges in a population of children and adolescents with ruptured appendicitis and discharge dates between March 1, 1999, and September 30, 2004. Pairwise regression analyses were performed to compare the most common monotherapy regimens with the triple therapy. RESULTS: A total of 8545 patients met the inclusion criteria, of whom 58%, over the entire study period, received the aminoglycoside-based triple antibiotic therapy on postoperative day 1. There was, however, a notable transition over this 6-year period, from 69% to 52% of surgeons using aminoglycoside-based combination therapy. There were no significant differences in the odds of readmission at 30 days except for the group receiving ceftriaxone, which was associated with significantly decreased odds. The subgroup receiving piperacillin/tazobactam monotherapy demonstrated significantly decreased length of stay (-0.90 days) and total hospital charges, and the group receiving cefoxitin demonstrated significantly decreased length of stay (-1.89 days), as well as decreased pharmacy and total hospital charges. CONCLUSIONS: Single-agent antibiotic therapy in the treatment of perforated appendicitis is being used with increasing frequency, is at least equal in efficacy to the traditional aminoglycoside-based combination therapy, and may offer improvements in terms of length of stay, pharmacy charges, and hospital charges.
OBJECTIVE: We conducted a retrospective cohort study to compare the use of triple therapy versus monotherapy for children and adolescents with perforated appendicitis and to determine whether there has been a transition to monotherapy within the freestanding children's hospitals that contribute to the Pediatric Health Information System database. METHODS: We used the Pediatric Health Information System database, which includes billing and discharge data for 32 children's hospitals in the United States, to examine the trend in antibiotic usage and whether the postappendectomy antibiotic regimen was associated with differences in complication-related readmissions, length of stay, or charges in a population of children and adolescents with ruptured appendicitis and discharge dates between March 1, 1999, and September 30, 2004. Pairwise regression analyses were performed to compare the most common monotherapy regimens with the triple therapy. RESULTS: A total of 8545 patients met the inclusion criteria, of whom 58%, over the entire study period, received the aminoglycoside-based triple antibiotic therapy on postoperative day 1. There was, however, a notable transition over this 6-year period, from 69% to 52% of surgeons using aminoglycoside-based combination therapy. There were no significant differences in the odds of readmission at 30 days except for the group receiving ceftriaxone, which was associated with significantly decreased odds. The subgroup receiving piperacillin/tazobactam monotherapy demonstrated significantly decreased length of stay (-0.90 days) and total hospital charges, and the group receiving cefoxitin demonstrated significantly decreased length of stay (-1.89 days), as well as decreased pharmacy and total hospital charges. CONCLUSIONS: Single-agent antibiotic therapy in the treatment of perforated appendicitis is being used with increasing frequency, is at least equal in efficacy to the traditional aminoglycoside-based combination therapy, and may offer improvements in terms of length of stay, pharmacy charges, and hospital charges.
Authors: Brian T Fisher; Theoklis E Zaoutis; Kateri H Leckerman; Russell Localio; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2010-10 Impact factor: 3.167
Authors: Michael R Arnold; Blair A Wormer; Angela M Kao; David A Klima; Paul D Colavita; Graham H Cosper; Brant Todd Heniford; Andrew M Schulman Journal: Pediatr Surg Int Date: 2018-09-14 Impact factor: 1.827
Authors: Sara Jane Webb; Michelle M Garrison; Raphael Bernier; Abbi M McClintic; Bryan H King; Pierre D Mourad Journal: Autism Res Date: 2016-09-01 Impact factor: 5.216
Authors: Tellen D Bennett; Christian M Niedzwecki; E Kent Korgenski; Susan L Bratton Journal: Arch Phys Med Rehabil Date: 2013-03-06 Impact factor: 3.966
Authors: Tellen D Bennett; Mark Fluchel; Aimee O Hersh; Kristen N Hayward; Adam L Hersh; Thomas V Brogan; Rajendu Srivastava; Bryan L Stone; E Kent Korgenski; Michael B Mundorff; T Charles Casper; Susan L Bratton Journal: Arthritis Rheum Date: 2012-12
Authors: Kin Wai Edwin Chan; Kim Hung Lee; Jennifer Wai Cheung Mou; Sing Tak Cheung; Jennifer Dart Yin Sihoe; Yuk Him Tam Journal: Pediatr Surg Int Date: 2010-02 Impact factor: 1.827